Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 10/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29701003 | 0.87 | PIK3C3 (0.77) | PIK3C3NPY5R | |
| SCHEMBL20765374 | 0.87 | PIK3C3 (0.77) | PIK3C3NPY5R | |
| SCHEMBL29035847 | 0.83 | PIK3C3 (0.71) | PIK3C3CYP1A2CYP3A4CYP2C19NPY5R | |
| SCHEMBL20765433 | 0.81 | PIK3C3 (1.00) | PIK3C3CYP1A2CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL26612404 | 0.81 | PIK3C3 (0.79) | PIK3C3KIT | |
| SCHEMBL20774921 | 0.80 | PIK3C3 (0.80) | PIK3C3CYP3A4 | |
| SCHEMBL20765560 | 0.80 | PIK3C3 (1.00) | PIK3C3MAPK1 | |
| SCHEMBL20764978 | 0.78 | PIK3C3 (0.78) | PIK3C3CYP3A4 | |
| SCHEMBL22408453 | 0.77 | PIK3C3 (1.00) | PIK3C3CYP3A4KIT | |
| SCHEMBL29635307 | 0.77 | PIK3C3 (1.00) | PIK3C3CYP3A4KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250127790-A1 | COMBINATION THERAPY USING VPS34 INHIBITORS | DECIPHERA PHARMACEUTICALS, LLC | 2025-04-24 | — | — | US | claimed |
| EP-4384180-A1 | COMBINATION THERAPY OF VPS34 INHIBITORS AND STING AGONIST FOR USE IN THE TREATMENT OF CANCER | Deciphera Pharmaceuticals, LLC (US) | 2024-06-19 | — | — | EP | claimed |
| CN-118201619-A | Combination therapy of VPS34 inhibitors with STING agonists for the treatment of cancer | 德西费拉制药有限责任公司 | 2024-06-14 | — | — | CN | claimed |
| CN-117255686-A | Antiviral activity of VPS34 inhibitors | 德西费拉制药有限责任公司 | 2023-12-19 | — | — | CN | claimed |
| US-11780858-B2 | Pyridinamine-pyridone and pyrimidinamine-pyridone compounds | SPRINT BIOSCIENCE AB (SE) | 2023-10-10 | — | — | US | claimed |
| EP-4251163-A1 | ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS | Deciphera Pharmaceuticals, LLC (US) | 2023-10-04 | — | — | EP | claimed |
| EP-4169581-A1 | PYRIDINAMINE-PYRIDONE AND PYRIMIDINAMINE-PYRIDONE COMPOUNDS | Sprint Bioscience AB (SE) | 2023-04-26 | — | — | EP | claimed |
| CN-111094271-B | Pyridinamine-pyridinone compounds and pyrimidinamine-pyridinone compounds | 思普瑞特生物科学公司 | 2023-02-28 | — | — | CN | claimed |
| WO-2023019259-A1 | COMBINATION THERAPY OF VPS34 INHIBITORS AND STING AGONIST FOR USE IN THE TREATMENT OF CANCER | DECIPHERA PHARMACEUTICALS, LLC (US) | 2023-02-16 | — | — | WO | claimed |
| EP-3672948-B1 | PYRIDINAMINE-PYRIDONE AND PYRIMIDINAMINE-PYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2022-10-05 | — | — | EP | claimed |
| US-20220184077-A1 | ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS | DECIPHERA PHARMACEUTICALS, LLC | 2022-06-16 | — | — | US | claimed |
| US-20220177495-A1 | PYRIDINAMINE-PYRIDONE AND PYRIMIDINAMINE-PYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2022-06-09 | — | — | US | claimed |
| WO-2022115546-A1 | ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2022-06-02 | — | — | WO | claimed |
| US-11208423-B2 | Pyridinamine-pyridone and pyrimidinamine- pyridone compounds | SPRINT BIOSCIENCE AB (SE) | 2021-12-28 | — | — | US | claimed |
| US-20200361963-A1 | PYRIDINAMINE-PYRIDONE AND PYRIMIDINAMINE-PYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2020-11-19 | — | — | US | claimed |
| CN-111094271-A | Pyridinamine-pyridinone compounds and pyrimidinamine-pyridinone compounds | 思普瑞特生物科学公司 | 2020-05-01 | — | — | CN | claimed |
| US-20250127790-A1 | COMBINATION THERAPY USING VPS34 INHIBITORS | DECIPHERA PHARMACEUTICALS, LLC | 2025-04-24 | — | — | US | disclosed |
| EP-4384180-A1 | COMBINATION THERAPY OF VPS34 INHIBITORS AND STING AGONIST FOR USE IN THE TREATMENT OF CANCER | Deciphera Pharmaceuticals, LLC (US) | 2024-06-19 | — | — | EP | disclosed |
| CN-111094271-A | Pyridinamine-pyridinone compounds and pyrimidinamine-pyridinone compounds | 思普瑞特生物科学公司 | 2020-05-01 | — | — | CN | disclosed |
| WO-2019038389-A1 | PYRIDINAMINE-PYRIDONE AND PYRIMIDINAMINE-PYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2019-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250127790-A1 | COMBINATION THERAPY USING VPS34 INHIBITORS | STING1, TBK1, VPS4B | PIK3C3 1649/4885CYP1A2 4820/4885CYP3A4 4483/4885 |
| US-11780858-B2 | Pyridinamine-pyridone and pyrimidinamine-pyridone compounds | PDXK, PLPBP, PNPO | PIK3C3 3787/4885CYP1A2 399/4885CYP3A4 470/4885 |
| US-11208423-B2 | Pyridinamine-pyridone and pyrimidinamine- pyridone compounds | PDXK, PLPBP, PNPO | PIK3C3 3838/4885CYP1A2 340/4885CYP3A4 430/4885 |
| US-20220177495-A1 | PYRIDINAMINE-PYRIDONE AND PYRIMIDINAMINE-PYRIDONE COMPOUNDS | PDXK, PLPBP, PNPO | PIK3C3 3787/4885CYP1A2 399/4885CYP3A4 470/4885 |
| US-20200361963-A1 | PYRIDINAMINE-PYRIDONE AND PYRIMIDINAMINE-PYRIDONE COMPOUNDS | PDXK, PLPBP, PNPO | PIK3C3 3838/4885CYP1A2 340/4885CYP3A4 430/4885 |
| US-20220184077-A1 | ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS | SARS1, VPS26B, VPS4B | PIK3C3 1967/4885CYP1A2 4748/4885CYP3A4 3161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.